1     
CONTROLLED SUBSTANCES REVISIONS

2     
2020 GENERAL SESSION

3     
STATE OF UTAH

4     
Chief Sponsor: Paul Ray

5     
Senate Sponsor: Allen M. Christensen

6     

7     LONG TITLE
8     General Description:
9          This bill amends the list of controlled substances and the composition of the Controlled
10     Substances Advisory Committee.
11     Highlighted Provisions:
12          This bill:
13          ▸     adds a substance to the listed controlled substances in the Utah Controlled
14     Substances Act;
15          ▸     amends the composition of the Controlled Substances Advisory Committee; and
16          ▸     makes technical changes.
17     Money Appropriated in this Bill:
18          None
19     Other Special Clauses:
20          None
21     Utah Code Sections Affected:
22     AMENDS:
23          58-37-4.2, as last amended by Laws of Utah 2018, Chapter 146
24          58-38a-201, as last amended by Laws of Utah 2011, Chapter 60
25          58-38a-202, as last amended by Laws of Utah 2011, Chapter 60
26     

27     Be it enacted by the Legislature of the state of Utah:
28          Section 1. Section 58-37-4.2 is amended to read:
29          58-37-4.2. Listed controlled substances.
30          The following substances, their analogs, homologs, and synthetic equivalents are listed
31     controlled substances:
32          (1) AB-001;
33          (2) AB-PINACA;
34     N-[1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole-3-carboxamide;
35          (3) AB-FUBINACA; N-[1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)
36     methyl]-1H-indazole-3-carboxamide;
37          (4) AB-CHMINACA
38     (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide);
39          (5) ADB-CHMINACA (N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-
40     (cyclohexylmethyl)indazole-3-carboxamide);
41          (6) ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1oxobutan-2-yl)-1-
42     (4-fluorobenzyl)-1H-indazole-3-caboxamide);
43          (7) AKB48;
44          (8) alpha-Pyrrolidinohexanophenone (alpha-PHP)
45     (1-Phenyl-2-(pyrrolidin-1-yl)hexan-1-one);
46          (9) alpha-Pyrrolidinovalerophenone (alpha-PVP);
47          (10) AM-694 (1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl)methanone);
48          (11) AM-1248;
49          (12) AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole);
50          (13) AM-2233;
51          (14) AM-679;
52          (15) A796,260;
53          (16) Butylone;
54          (17) CP 47,497 and its C6, C8, and C9 homologs (2-[(1R,3S)-3-hydroxycyclohexyl]
55     -5-(2-methyloctan-2-yl)phenol);
56          (18) Diisopropyltryptamine (DiPT);
57          (19) Ethylone;
58          (20) Ethylphenidate;
59          (21) Fluoroisocathinone;
60          (22) Fluoromethamphetamine;
61          (23) Fluoromethcathinone;
62          (24) FUB-AMB; methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)valinate;
63          (25) HU-210; (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
64     -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
65          (26) HU-211; Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-
66     methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
67          (27) JWH-015; (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenyl-methanone;
68          (28) JWH-018; Naphthalen-1-yl-(pentylindol-3-yl)methanone {also known as
69     1-Pentyl-3-(1-naphthoyl)indole};
70          (29) JWH-019; 1-hexyl-3-(1-naphthoyl)indole;
71          (30) JWH-073; Naphthalen-1-yl(1-butylindol-3-yl)methanone {also known as
72     1-Butyl-3-(1-naphthoyl)indole};
73          (31) JWH-081; 4-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone;
74          (32) JWH-122; CAS#619294-47-2; (1-Pentyl-3-(4-methyl-1-naphthoyl)indole);
75          (33) JWH-200; 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl)indole;
76          (34) JWH-203; 1-pentyl-3-(2-chlorophenylacetyl)indole;
77          (35) JWH-210; 4-ethyl-1-naphthalenyl(1-pentyl-1H-indol-3-yl)-methanone;
78          (36) JWH-250; 1-pentyl-3-(2-methoxyphenylacetyl)indole;
79          (37) JWH-251; 2-(2-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone;
80          (38) JWH-398; 1-pentyl-3-(4-chloro-1-naphthoyl)indole;
81          (39) MAM-2201;
82          (40) MAM-2201;
83     (1-(5-fluoropentyl)-1H-indol-3-yl)(4-ethyl-1-naphthalenyl)-methanone;
84          (41) Methoxetamine;
85          (42) Naphyrone;
86          (43) PB-22; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester;
87          (44) Pentedrone;
88          (45) Pentylone;
89          (46) RCS-4; 1-pentyl-3-(4-methoxybenzoyl)indole;
90          (47) RCS-8; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole {also known as
91     BTW-8 and SR-18};
92          (48) STS-135;
93          (49) UR-144;
94          (50) UR-144 N-(5-chloropentyl) analog;
95          (51) XLR11;
96          (52) 2C-C;
97          (53) 2C-D;
98          (54) 2C-E;
99          (55) 2C-H;
100          (56) 2C-I;
101          (57) 2C-N;
102          (58) 2C-P;
103          (59) 2C-T-2;
104          (60) 2C-T-4;
105          (61) 2NE1;
106          (62) 25I-NBOMe;
107          (63) 2,5-Dimethoxy-4-chloroamphetamine (DOC);
108          (64) 4-Fluoro MDMB-BUTINACA (Methyl
109     2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate);
110          [(64)] (65) 4-methylmethcathinone {also known as mephedrone};
111          [(65)] (66) 3,4-methylenedioxypyrovalerone {also known as MDPV};
112          [(66)] (67) 3,4-Methylenedioxymethcathinone {also known as methylone};
113          [(67)] (68) 4-methoxymethcathinone;
114          [(68)] (69) 4-Methyl-alpha-pyrrolidinopropiophenone;
115          [(69)] (70) 4-Methylethcathinone;
116          [(70)] (71) 5F-AKB48;
117     1-(5-flouropentyl)-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3- carboxamide;
118          [(71)] (72) 5-Fluoro ADB (Methyl
119     N-{[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl}-3-methyl-valinate);
120          [(72)] (73) 5-Fluoro AMB (Methyl
121     N-{[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl}valinate);
122          [(73)] (74) 5-fluoro-PB-22; 1-(5-fluoropentyl)-1H-indole-3-carboxylic acid
123     8-quinolinyl ester;
124          [(74)] (75) 5-Iodo-2-aminoindane (5-IAI);
125          [(75)] (76) 5-MeO-DALT;
126          [(76)] (77) 25B-NBOMe; 2-(r-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)
127     methyl]ethanamine;
128          [(77)] (78) 25C-NBOMe; 2-(4Chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)
129     methyl]ethanamine; and
130          [(78)] (79) 25H-NBOMe;
131     2-(2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine.
132          Section 2. Section 58-38a-201 is amended to read:
133          58-38a-201. Controlled Substances Advisory Committee.
134          There is created within the Division of Occupational and Professional Licensing the
135     Controlled Substances Advisory Committee. The committee consists of:
136          (1) the director of the Department of Health or the director's designee;
137          (2) the State Medical Examiner or the examiner's designee;
138          (3) the commissioner of the Department of Public Safety or the commissioner's
139     designee;
140          (4) the director of the Bureau of Forensic Services created in Section 53-10-401, or the
141     director's designee;
142          (5) the director of the Utah Poison Control Center or the director's designee;
143          [(4)] (6) one physician who is a member of the Physicians Licensing Board and is
144     designated by that board;
145          [(5)] (7) one pharmacist who is a member of the Utah State Board of Pharmacy and is
146     designated by that board;
147          [(6)] (8) one dentist who is a member of the Dentist and Dental Hygienist Licensing
148     Board and is designated by that board;
149          [(7)] (9) one physician who is currently licensed and practicing in the state, to be
150     appointed by the governor;
151          [(8)] (10) one psychiatrist who is currently licensed and practicing in the state, to be
152     appointed by the governor;
153          [(9)] (11) one individual with expertise in substance abuse addiction, to be appointed
154     by the governor;
155          [(10)] (12) one representative from the Statewide Association of Prosecutors, to be
156     designated by that association;
157          [(11)] (13) one naturopathic physician who is currently licensed and practicing in the
158     state, to be appointed by the governor;
159          [(12)] (14) one advanced practice registered nurse who is currently licensed and
160     practicing in this state, to be appointed by the governor; and
161          [(13)] (15) one member of the public, to be appointed by the governor.
162          Section 3. Section 58-38a-202 is amended to read:
163          58-38a-202. Terms of committee service.
164          (1) (a) Members of the advisory committee shall serve terms of four years, except that
165     the members under Subsections 58-38a-201(1), (2), [and] (3), and (4) shall serve during their
166     terms as appointed officials.
167          (b) Vacancies in the committee occurring otherwise than by the expiration of a term
168     shall be filled for the unexpired term in the same manner as original appointments.
169          (2) A member may not receive compensation or benefits for the member's service, but
170     may receive per diem and travel expenses in accordance with:
171          (a) Section 63A-3-106;
172          (b) Section 63A-3-107; and
173          (c) rules made by the Division of Finance pursuant to Sections 63A-3-106 and
174     63A-3-107.
175          (3) (a) The director of the Department of Health, or the director's designee, is the chair
176     of the committee.
177          (b) The advisory committee meets at the call of the chair or at the call of a majority of
178     the committee members.
179          (c) The advisory committee meets annually and more often as required to carry out its
180     duties under this chapter.
181          (d) Seven members of the advisory committee constitute a quorum.
182          (e) Action by the committee requires a majority vote of a quorum.